India pharma sector shifts from generics to high-value innovation and biologics

What Happened

• India's pharmaceutical sector is undergoing a strategic shift: moving beyond bulk generics — the traditional strength — into complex generics, biosimilars, biologics, and AI-integrated smart manufacturing.
• Pharmaceutical exports crossed USD 30 billion in FY 2024-25, growing over 9% year-on-year, with projections to reach USD 75–80 billion by end of the decade.
• India holds the world's largest portfolio of approved domestic biosimilars — over 135 approved products — and is positioned to capture significant share as over 39 high-value biologic patents expire globally between 2025 and 2032.
• The Production Linked Incentive (PLI) scheme for pharmaceuticals generated cumulative sales of ₹3.08 lakh crore since inception (through September 2025), with exports of ₹1.98 lakh crore and investments of ₹40,294 crore — significantly exceeding the original investment target of ₹17,275 crore.
• The Biopharma SHAKTI initiative (Budget 2026-27) provides ₹10,000 crore over five years for biologics and biosimilars manufacturing, expansion of NIPER (National Institute of Pharmaceutical Education and Research) institutes, and development of over 1,000 clinical trial sites.

Static Topic Bridges

Biosimilars and Biologics — Definitions and Significance

A biologic is a medicinal product derived from living cells — proteins, monoclonal antibodies, vaccines, cell and gene therapies — as opposed to chemically synthesised small-molecule drugs. A biosimilar is a biologic medicine that is highly similar in structure and clinical effect to an already-approved reference biologic, developed after the original's patent expires. Biosimilars are significantly more complex to manufacture than generic small-molecule drugs: they require living cell culture systems, sophisticated purification, and extensive analytical characterisation. India has become a global leader in biosimilar manufacturing given its large pool of trained biotechnology talent, established USFDA-approved facilities, and cost advantages of 40–60% below Western manufacturers.

Production Linked Incentive (PLI) Scheme for Pharmaceuticals

The PLI scheme for pharmaceuticals was announced to incentivise domestic production of high-value pharmaceutical products including complex generics, patented drugs, biosimilars, biopharmaceuticals, active pharmaceutical ingredients (APIs), and medical devices. It provides financial incentives of 3–10% on incremental sales over a base year, structured across three cohorts targeting different product categories: Category 1 (biopharmaceuticals), Category 2 (APIs and key starting materials), Category 3 (repurposed drugs). The scheme reversed India's dependence on Chinese API imports — a vulnerability exposed during the COVID-19 supply chain disruption.

Biopharma SHAKTI Initiative

Announced in Union Budget 2026-27, the Biopharma SHAKTI (Supporting High-value Advancements with Knowledge and Technology in India) initiative is a dedicated policy instrument for India's biopharmaceutical sector. The initiative carries an outlay of ₹10,000 crore over five years, focusing on three pillars: (1) boosting biologics and biosimilars manufacturing capacity; (2) expanding research and education through NIPER institutes; and (3) developing over 1,000 clinical trial sites across the country to enable India to participate more fully in global drug development.

USFDA Approvals and India's Regulatory Advantage

India has the largest number of USFDA-approved drug manufacturing facilities outside the United States — over 600 facilities, accounting for approximately 40% of generic drugs and ~10% of finished dosage forms consumed in the US. This approval base is a major entry barrier for competitors and a trust signal for US/EU buyers. Recent USFDA regulatory reforms — including simplifying biosimilar approval by reducing the need for comparative clinical trials and allowing greater reliance on analytical characterisation — disproportionately benefit India's analytically strong manufacturing base.

AI and Smart Manufacturing in Pharmaceuticals

Artificial intelligence is transforming pharmaceutical manufacturing across the value chain: in drug discovery (de novo molecule design, target identification), quality control (real-time process analytical technology), clinical trials (patient stratification, site selection, decentralised trials), and supply chain optimisation. For Indian manufacturers, AI integration enables higher-quality production at lower cost, reduces batch failure rates, and accelerates regulatory submissions through AI-generated documentation and bioequivalence modelling.

Key Facts & Data

• India's pharma export value (FY 2024-25): USD 30 billion+ (9%+ YoY growth)
• Export target (end of decade): USD 75–80 billion
• India's global pharma rank: 3rd largest by volume; 14th by value
• Approved domestic biosimilars: 135+ (largest among emerging markets globally)
• Biosimilars market CAGR: ~22%; projected USD 12 billion by 2025
• Biologic patents expiring globally (2025-2032): 39+
• USFDA-approved pharma facilities in India: 600+
• PLI scheme sales generated: ₹3.08 lakh crore (through September 2025)
• PLI exports: ₹1.98 lakh crore
• PLI investment attracted: ₹40,294 crore (original target: ₹17,275 crore)
• Biopharma SHAKTI outlay: ₹10,000 crore over five years (Budget 2026-27)
• Clinical trial sites target: 1,000+ (under Biopharma SHAKTI)
• India's share of US generic consumption: ~40%
• India's pharma market projection (2030): USD 130 billion (ASSOCHAM estimate)
• NIPER institutes: National Institutes of Pharmaceutical Education and Research — to be expanded under Biopharma SHAKTI
• Strategic shift: Bulk generics → Complex generics → Biosimilars → Biologics → AI-driven innovation